A2 Biotherapeutics is designing novel cell therapies to treat serious illnesses. Therapeutics to treat cancers depend on methods to distinguish tumors from normal cells. A2 Bio is using their proprietary Tmod platform to innovate new treatments for solid tumors involving the immune system. The platform integrates multiple signals, overcoming conventional single-target therapies, and exploits tumor-specific vulnerabilities. The Tmod platform is robustly different from other cell therapy systems due to its tumor precision and efficacy by incorporating two receptors, an activator and a blocker, to modulate the immune system. As their platform is modular, A2 Bio is building a broad pipeline of both autologous and allogeneic cell therapies for many unexploited tumor targets. 

<p>A2 Biotherapeutics is designing novel cell therapies to treat serious illnesses. Therapeutics to treat cancers depend on methods to distinguish tumors from normal cells. A2 Bio is using their proprietary Tmod platform to innovate new treatments for solid tumors involving the immune system. The platform integrates multiple signals, overcoming conventional single-target therapies, and exploits tumor-specific vulnerabilities. The Tmod platform is robustly different from other cell therapy systems due to its tumor precision and efficacy by incorporating two receptors, an activator and a blocker, to modulate the immune system. As their platform is modular, A2 Bio is building a broad pipeline of both autologous and allogeneic cell therapies for many unexploited tumor targets. </p>


A2 Biotherapeutics

Founded: 2017
Location: Agoura Hills, CA
Employee range: 50 - 200
Clinical stage: Clin1
Therapy area: Multiple cancers
Drug types: ONC
Lead product: A2B530
Funding: $71.5M B Oct 2020; $57M A Nov 2019

Business:

Drug notes:

About:

Jobs:

News: